Time course of cardiac inflammation during nitric oxide synthase inhibition in SHR: impact of prior transient ACE inhibition

Hypertens Res. 2016 Jan;39(1):8-18. doi: 10.1038/hr.2015.107. Epub 2015 Oct 22.

Abstract

We have previously demonstrated that angiotensin-converting enzyme (ACE) inhibition with enalapril produces persistent effects that protect against future nitric oxide synthase (NOS) inhibitor (L-arginine methyl ester, L-NAME)-induced cardiac dysfunction and outer wall collagen deposition in spontaneously hypertensive rats (SHR). In the present study, we dissect the cytokine/chemokine release profile during NOS inhibition, its correlation to pathological cardiac remodeling and the impact of transient ACE inhibition on these effects. Adult male SHR were treated with enalapril (E+L) or tap water (C+L) for 2 weeks followed by a 2-week washout period. Rats were then subjected to 0, 3, 7 or 10 days of L-NAME treatment. The temporal response to NOS inhibition was evaluated by measuring arterial pressure, cardiac remodeling and cytokine/chemokine levels. L-NAME equivalently increased blood pressure and myocardial and vascular injury in C+L and E+L rats. However, pulse pressure (PP) was only transiently altered in C+L rats. The levels of several inflammatory mediators were increased during L-NAME treatment. However, interleukin-6 (IL-6) and IL-10 and monocyte chemoattractant protein-1 were uniquely increased in C+L hearts; whereas IL-4 and fractalkine were only elevated in E+L hearts. By days 7 and 10 of L-NAME treatment, there was a significant increase in the cardiac density of macrophages and proliferating cells, respectively only in C+L rats. Although myocardial injury was similar in both treatment groups, PP was not changed and there was a distinct cardiac chemokine/cytokine signature in rats previously treated with enalapril that may be related to the lack of proliferative response and macrophage infiltration in these hearts.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Animals
  • Arterial Pressure / drug effects
  • Cell Proliferation / drug effects
  • Chemokine CCL2 / blood
  • Chemokines
  • Cytokines / metabolism
  • Disease Progression
  • Enalapril / pharmacology
  • Enzyme Inhibitors / pharmacology*
  • Interleukin-10 / blood
  • Interleukin-6 / blood
  • Macrophages / drug effects
  • Male
  • Myocarditis / chemically induced
  • Myocarditis / pathology*
  • Myocarditis / prevention & control
  • NG-Nitroarginine Methyl Ester / pharmacology*
  • Nitric Oxide Synthase / antagonists & inhibitors*
  • Rats
  • Rats, Inbred SHR

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Ccl2 protein, rat
  • Chemokine CCL2
  • Chemokines
  • Cytokines
  • Enzyme Inhibitors
  • Interleukin-6
  • Interleukin-10
  • Enalapril
  • Nitric Oxide Synthase
  • NG-Nitroarginine Methyl Ester